Foundry ShareIss1Y Industry-Neutral Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 16.89% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 9.27% |
3ABBV | ABBVIE INC | Healthcare | $449.63B | 6.84% |
4KO | COCA COLA CO | Consumer Defensive | $350.91B | 5.34% |
5MRK | MERCK & CO INC | Healthcare | $314.90B | 4.79% |
6PM | PHILIP MORRIS INTERNATIONAL INC | Consumer Defensive | $300.77B | 4.58% |
7AMGN | AMGEN INC | Healthcare | $197.69B | 3.01% |
8PEP | PEPSICO INC | Consumer Defensive | $187.15B | 2.85% |
9ABT | ABBOTT LABORATORIES | Healthcare | $175.37B | 2.67% |
10GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 2.54% |
11PFE | PFIZER INC | Healthcare | $142.77B | 2.17% |
12BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 1.89% |
13MO | ALTRIA GROUP INC | Consumer Defensive | $123.92B | 1.89% |
14VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 1.88% |
15SYK | STRYKER CORP | Healthcare | $122.63B | 1.87% |
16ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 1.86% |
17PH | PARKER-HANNIFIN CORP | Industrials | $120.19B | 1.83% |
18MDT | MEDTRONIC PLC | Healthcare | $106.50B | 1.62% |
19MMM | 3M CO | Industrials | $83.37B | 1.27% |
20REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 1.08% |
21BSX | BOSTON SCIENTIFIC CORP | Healthcare | $65.44B | 1.00% |
22EW | EDWARDS LIFESCIENCES CORP | Healthcare | $49.36B | 0.75% |
23IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.68% |
24BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 0.66% |
25KDP | KEURIG DR PEPPER INC | Consumer Defensive | $42.05B | 0.64% |
26TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 0.57% |
27ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.54% |
28ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.53% |
29RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 0.51% |
30ZTS | ZOETIS INC | Healthcare | $32.10B | 0.49% |
31BIIB | BIOGEN INC | Healthcare | $30.41B | 0.46% |
32DXCM | DEXCOM INC | Healthcare | $29.58B | 0.45% |
33RMD | RESMED INC | Healthcare | $28.86B | 0.44% |
34GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 0.44% |
35AMRZ | AMRIZE LTD | Basic Materials | $27.53B | 0.42% |
36ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 0.38% |
37MRNA | MODERNA INC | Healthcare | $24.53B | 0.37% |
38UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.35% |
39STZ | CONSTELLATION BRANDS INC | Consumer Defensive | $22.69B | 0.35% |
40SNA | SNAP-ON INC | Industrials | $21.29B | 0.32% |
41STE | STERIS PLC | Healthcare | $21.26B | 0.32% |
42VTRS | VIATRIS INC | Healthcare | $20.14B | 0.31% |
43ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $17.63B | 0.27% |
44NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.26% |
45BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.94B | 0.24% |
46MAS | MASCO CORP | Basic Materials | $15.87B | 0.24% |
47JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 0.24% |
48SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 0.21% |
49SWK | STANLEY BLACK & DECKER INC | Industrials | $14.02B | 0.21% |
50COO | COOPER COMPANIES INC | Healthcare | $13.99B | 0.21% |
51ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $12.90B | 0.20% |
52MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 0.19% |
53ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.19% |
54CR | CRANE CO | Industrials | $12.56B | 0.19% |
55PEN | PENUMBRA INC | Healthcare | $12.52B | 0.19% |
56AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 0.18% |
57BF.B | BROWN FORMAN CORP | Consumer Defensive | $11.74B | 0.18% |
58BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 0.18% |
59OC | OWENS CORNING | Basic Materials | $11.59B | 0.18% |
60WTS | WATTS WATER TECHNOLOGIES INC | Industrials | $11.57B | 0.18% |
61HAS | HASBRO INC | Consumer Cyclical | $11.54B | 0.18% |
62BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 0.18% |
63PODD | INSULET CORP | Healthcare | $11.36B | 0.17% |
64TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 0.17% |
65SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $10.72B | 0.16% |
66ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.16% |
67KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.16% |
68GMED | GLOBUS MEDICAL INC | Healthcare | $10.45B | 0.16% |
69VMI | VALMONT INDUSTRIES INC | Industrials | $10.32B | 0.16% |
70CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 0.15% |
71NUVL | NUVALENT INC | Healthcare | $9.79B | 0.15% |
72CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.15% |
73HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.14% |
74GKOS | GLAUKOS CORP | Healthcare | $9.21B | 0.14% |
75PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 0.14% |
76IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.14% |
77ALKS | ALKERMES PLC | Healthcare | $8.79B | 0.13% |
78TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.13% |
79RGEN | REPLIGEN CORP | Healthcare | $8.31B | 0.13% |
80SSD | SIMPSON MANUFACTURING CO INC | Basic Materials | $7.78B | 0.12% |
81RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.31B | 0.11% |
82TAP | MOLSON COORS BEVERAGE CO | Consumer Defensive | $7.28B | 0.11% |
83ACA | ARCOSA INC | Industrials | $7.12B | 0.11% |
84LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.11% |
85LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.11% |
86RIOT | RIOT PLATFORMS INC | Financial Services | $6.91B | 0.11% |
87GOLF | ACUSHNET HOLDINGS CORP | Consumer Cyclical | $6.72B | 0.10% |
88MSA | MSA SAFETY INC | Industrials | $6.60B | 0.10% |
89PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 0.10% |
90EXP | EAGLE MATERIALS INC | Basic Materials | $6.37B | 0.10% |
91LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.09% |
92ERAS | ERASCA INC | Healthcare | $5.96B | 0.09% |
93TFX | TELEFLEX INC | Healthcare | $5.96B | 0.09% |
94TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 0.09% |
95BLCO | BAUSCH & LOMB CORP | Healthcare | $5.80B | 0.09% |
96AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $5.69B | 0.09% |
97TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.08% |
98LPX | LOUISIANA-PACIFIC CORP | Basic Materials | $5.17B | 0.08% |
99KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.07% |
100UFPI | UFP INDUSTRIES INC | Basic Materials | $4.85B | 0.07% |
101TREX | TREX CO INC | Basic Materials | $4.69B | 0.07% |
102SKY | CHAMPION HOMES INC | Consumer Cyclical | $4.54B | 0.07% |
103LIVN | LIVANOVA PLC | Healthcare | $4.43B | 0.07% |
104MMSI | MERIT MEDICAL SYSTEMS INC | Healthcare | $4.41B | 0.07% |
105ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.07% |
106NVST | ENVISTA HOLDINGS CORP | Healthcare | $4.35B | 0.07% |
107CVCO | CAVCO INDUSTRIES INC | Consumer Cyclical | $4.35B | 0.07% |
108VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.07% |
109EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $4.28B | 0.07% |
110GFF | GRIFFON CORP | Industrials | $4.20B | 0.06% |
111COCO | VITA COCO COMPANY INC | Consumer Defensive | $4.18B | 0.06% |
112MAT | MATTEL INC | Consumer Cyclical | $4.15B | 0.06% |
113MWA | MUELLER WATER PRODUCTS INC | Industrials | $3.98B | 0.06% |
114ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 0.06% |
115YETI | YETI HOLDINGS INC | Consumer Cyclical | $3.87B | 0.06% |
116CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.06% |
117DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.70B | 0.06% |
118ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $3.67B | 0.06% |
119IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.64B | 0.06% |
120ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.05% |
121OGN | ORGANON & CO | Healthcare | $3.55B | 0.05% |
122HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.05% |
123CALY | CALLAWAY GOLF CO | Consumer Cyclical | $3.48B | 0.05% |
124WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.05% |
125IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.05% |
126KN | KNOWLES CORP | Technology | $3.01B | 0.05% |
127CXT | CRANE NXT CO | Industrials | $2.95B | 0.04% |
128IRON | DISC MEDICINE INC | Healthcare | $2.91B | 0.04% |
129PATK | PATRICK INDUSTRIES INC | Consumer Cyclical | $2.90B | 0.04% |
130RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.04% |
131BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 0.04% |
132RUN | SUNRUN INC | Technology | $2.83B | 0.04% |
133SMR | NUSCALE POWER CORP | Industrials | $2.82B | 0.04% |
134XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.04% |
135SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.04% |
136ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.72B | 0.04% |
137HLIO | HELIOS TECHNOLOGIES INC | Industrials | $2.68B | 0.04% |
138TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.04% |
139TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.04% |
140PTON | PELOTON INTERACTIVE INC | Consumer Cyclical | $2.55B | 0.04% |
141VCEL | VERICEL CORP | Healthcare | $2.38B | 0.04% |
142PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.04% |
143AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 0.04% |
144LMAT | LEMAITRE VASCULAR INC | Healthcare | $2.32B | 0.04% |
145NEOG | NEOGEN CORP | Healthcare | $2.24B | 0.03% |
146SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.03% |
147AXGN | AXOGEN INC | Healthcare | $2.12B | 0.03% |
148TGLS | TECNOGLASS INC | Basic Materials | $2.06B | 0.03% |
149AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.03% |
150NUVB | NUVATION BIO INC | Healthcare | $2.03B | 0.03% |
151SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.03% |
152ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.03% |
153PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.03% |
154ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.03% |
155URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.03% |
156HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.03% |
157UFPT | UFP TECHNOLOGIES INC | Healthcare | $1.87B | 0.03% |
158MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.03% |
159SAM | BOSTON BEER CO INC | Consumer Defensive | $1.86B | 0.03% |
160PRLB | PROTO LABS INC | Industrials | $1.85B | 0.03% |
161NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.03% |
162SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.03% |
163ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.03% |
164SONO | SONOS INC | Technology | $1.80B | 0.03% |
165IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.03% |
166ATRC | ATRICURE INC | Healthcare | $1.77B | 0.03% |
167ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.03% |
168HROW | HARROW INC | Healthcare | $1.74B | 0.03% |
169BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.03% |
170ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.03% |
171EYE | NATIONAL VISION HOLDINGS INC | Consumer Cyclical | $1.66B | 0.03% |
172TPB | TURNING POINT BRANDS INC | Consumer Defensive | $1.60B | 0.02% |
173HLMN | HILLMAN SOLUTIONS CORP | Industrials | $1.59B | 0.02% |
174XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.02% |
175SEPN | SEPTERNA INC | Healthcare | $1.51B | 0.02% |
176IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.50B | 0.02% |
177PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.02% |
178INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.02% |
179ARLO | ARLO TECHNOLOGIES INC | Basic Materials | $1.45B | 0.02% |
180KMTS | KESTRA MEDICAL TECHNOLOGIES LTD | Healthcare | $1.43B | 0.02% |
181BLFS | BIOLIFE SOLUTIONS INC | Healthcare | $1.42B | 0.02% |
182PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.02% |
183NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.02% |
184BW | BABCOCK & WILCOX ENTERPRISES INC | Industrials | $1.35B | 0.02% |
185STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 0.02% |
186ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.31B | 0.02% |
187CNMD | CONMED CORP | Healthcare | $1.30B | 0.02% |
188XNCR | XENCOR INC | Healthcare | $1.30B | 0.02% |
189ARDX | ARDELYX INC | Healthcare | $1.28B | 0.02% |
190INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.02% |
191CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $1.25B | 0.02% |
192CDRE | CADRE HOLDINGS INC | Industrials | $1.24B | 0.02% |
193IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.02% |
194AORT | ARTIVION INC | Healthcare | $1.22B | 0.02% |
195DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.19B | 0.02% |
196QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.02% |
197TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.02% |
198COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.02% |
199AVNS | AVANOS MEDICAL INC | Healthcare | $1.17B | 0.02% |
200ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.02% |
201SDGR | SCHRODINGER INC | Healthcare | $1.14B | 0.02% |
202PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.09B | 0.02% |
203CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $1.09B | 0.02% |
204PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.02% |
205BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.02% |
206JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 0.02% |
207KURA | KURA ONCOLOGY INC | Healthcare | $964M | 0.01% |
208KOP | KOPPERS HOLDINGS INC | Basic Materials | $945M | 0.01% |
209TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.01% |
210AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.01% |
211REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 0.01% |
212CYRX | CRYOPORT INC | Industrials | $832M | 0.01% |
213AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.01% |
214DSGN | DESIGN THERAPEUTICS INC | Healthcare | $785M | 0.01% |
215SIBN | SI-BONE INC | Healthcare | $771M | 0.01% |
216BBNX | BETA BIONICS INC | Healthcare | $771M | 0.01% |
217ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.01% |
218RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.01% |
219WEST | WESTROCK COFFEE CO | Consumer Defensive | $749M | 0.01% |
220MNPR | MONOPAR THERAPEUTICS | Healthcare | $744M | 0.01% |
221JBI | JANUS INTERNATIONAL GROUP INC | Basic Materials | $737M | 0.01% |
222CLYM | CLIMB BIO INC | Healthcare | $727M | 0.01% |
223CBLL | CERIBELL INC | Healthcare | $710M | 0.01% |
224SPRY | ARS PHARMACEUTICALS INC | Healthcare | $695M | 0.01% |
225TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.01% |
226LEGH | LEGACY HOUSING CORP | Consumer Cyclical | $637M | 0.01% |
227TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.01% |
228GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.01% |
229MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.01% |
230ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.01% |
231NPCE | NEUROPACE INC | Healthcare | $548M | 0.01% |
232ARVN | ARVINAS INC | Healthcare | $517M | 0.01% |
233RGNX | REGENXBIO INC | Healthcare | $511M | 0.01% |
234XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.01% |
235KIDS | ORTHOPEDIATRICS CORP | Healthcare | $494M | 0.01% |
236JOUT | JOHNSON OUTDOORS INC | Consumer Cyclical | $485M | 0.01% |
237OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.01% |
238CLPT | CLEARPOINT NEURO INC | Healthcare | $454M | 0.01% |
239PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.01% |
240SI | SHOULDER INNOVATIONS INC | Healthcare | $448M | 0.01% |
241DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.01% |
242PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.01% |
243USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $403M | 0.01% |
244EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.01% |
245UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.01% |
246EOLS | EVOLUS INC | Healthcare | $377M | 0.01% |
247ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.01% |
248NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.01% |
249ELMD | ELECTROMED INC | Healthcare | $349M | 0.01% |
250CV | CAPSOVISION INC | Healthcare | $335M | 0.01% |
251VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.00% |
252FNKO | FUNKO INC | Consumer Cyclical | $326M | 0.00% |
253CARL | CARLSMED INC | Healthcare | $317M | 0.00% |
254CIX | COMPX INTERNATIONAL INC | Industrials | $309M | 0.00% |
255FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.00% |
256OFLX | OMEGA FLEX INC | Industrials | $302M | 0.00% |
257TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.00% |
258JAKK | JAKKS PACIFIC INC | Consumer Cyclical | $277M | 0.00% |
259SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.00% |
260TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.00% |
261ESCA | ESCALADE INC | Consumer Cyclical | $266M | 0.00% |
262ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.00% |
263GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $240M | 0.00% |
264RXST | RXSIGHT INC | Healthcare | $230M | 0.00% |
265SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.00% |
266UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.00% |
267KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.00% |
268FOCL | FOCAL INC | Healthcare | $204M | 0.00% |
269ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.00% |
270LCUT | LIFETIME BRANDS INC | Consumer Cyclical | $195M | 0.00% |
271PDEX | PRO DEX INC | Healthcare | $183M | 0.00% |
272ACU | ACME UNITED CORP | Consumer Defensive | $181M | 0.00% |
273INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
274INGN | INOGEN INC | Healthcare | $178M | 0.00% |
275ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.00% |
276LENZ | LENZ THERAPEUTICS INC | Healthcare | $162M | 0.00% |
277RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.00% |
278EML | EASTERN CO | Industrials | $154M | 0.00% |
279SMID | SMITH MIDLAND CORP | Basic Materials | $152M | 0.00% |
280AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.00% |
281VATE | INNOVATE CORP | Industrials | $123M | 0.00% |
282LAKE | LAKELAND INDUSTRIES INC | Consumer Cyclical | $113M | 0.00% |
283FTLF | FITLIFE BRANDS INC | Consumer Defensive | $104M | 0.00% |
284CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.00% |
285ICCC | IMMUCELL CORP | Healthcare | $101M | 0.00% |
286RLYB | RALLYBIO CORP | Healthcare | $87M | 0.00% |
287CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
288NRXS | NEURAXIS INC | Healthcare | $84M | 0.00% |
289LFVN | LIFEVANTAGE CORP | Consumer Defensive | $78M | 0.00% |
290AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.00% |
291LNSR | LENSAR INC | Healthcare | $70M | 0.00% |
292SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
293APT | ALPHA PRO TECH LTD | Basic Materials | $53M | 0.00% |
294EXOZ | EXOZYMES INC | Healthcare | $51M | 0.00% |
295BKHA | BLACK HAWK ACQUISITION CORP | Industrials | $50M | 0.00% |
296TIL | INSTIL BIO INC | Healthcare | $50M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $6.57T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 73% toward Growth. +2% unclassified (34 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 296 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual64.4%Margin-39.4%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 296 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 34.6% | 16.2% |
| 3 yearsp.a. | 29.4% | 15.7% |
| 5 yearsp.a. | 18.0% | 15.0% |
| 10 yearsp.a. | 17.0% | 5.6% |
| Since inceptionp.a. | 9.3% | 3.4% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 17.8% | 5.7% |
| 2025 | 30.9% | 29.4% |
| 2024 | 34.0% | 15.4% |
| 2023 | 24.8% | -0.7% |
| 2022 | -20.5% | 15.9% |
| 2021 | 24.8% | 13.2% |
| 2020 | 6.7% | -34.8% |
| 2019 | 45.5% | 18.7% |
| 2018 | -3.6% | 2.2% |
| 2017 | 20.4% | 4.2% |
| 2016 | 7.7% | -3.5% |
| 2015 | 4.4% | 14.7% |
| 2014 | 22.4% | 11.1% |
| 2013 | 31.1% | -8.9% |
| 2012 | 21.3% | 5.0% |
| 2011 | 3.7% | 15.3% |
| 2010 | 21.3% | 7.2% |
| 2009 | 16.9% | -16.4% |
| 2008 | -30.6% | 48.2% |
| 2007 | 7.8% | 0.5% |
| 2006 | 18.4% | -0.7% |
| 2005 | 14.0% | 13.4% |
| 2004 | 22.1% | 8.7% |
| 2003 | 15.6% | -17.9% |
| 2002 | -22.3% | -2.9% |
| 2001 | -16.6% | 4.4% |
| 2000 | -25.5% | -12.1% |
| 1999 | 12.6% | -7.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry ShareIss1Y Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a ShareIss1Y signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.